LZAGY - Lonza finishes laboratory expansion at API manufacturing facility in China

Lonza (OTCPK:LZAGY) (OTCPK:LZAGF) completed laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site in Nansha, China. The company said the expansion , which grew the laboratory footprint to 250 square meters, focused on extending the capacity of development laboratories and kilogram-scale cGMP manufacturing laboratories for clinical supply of highly-potent APIs (HPAPI). “With over 1000 HPAPIs in development across multiple indications, there is a growing need for HPAPI development and manufacturing capacity from early-phase to commercial," said Jan Vertommen, executive director, commercial development, small molecules, Lonza. HPAPIs currently form a large part of Lonza’s small molecule development pipeline. The new laboratories are part of the company's recent investment to expand mid-scale manufacturing capacity at the Nansha site. The new laboratories will begin operations in March. “The expansion of our HPAPI capabilities at Nansha enables us to enter HPAPI manufacturing to meet growing global demand, especially in supporting clinical trials in oncology," said Jason

For further details see:

Lonza finishes laboratory expansion at API manufacturing facility in China